A systematic review that pooled 81 studies looking at Wegovy and a range of mental health symptoms did not find a consistent link between Wegovy and insomnia, so higher-quality evidence leans away from a simple cause-and-effect story
If you don't record it straight away - which I didn't in this case - then it can get forgotten because you have all these other things
Insulin is the clearest example of the perverse rebate dynamic because the clinical products are largely interchangeable the difference between Novolog, Humalog, and their biosimilar equivalents is not clinically meaningful for most patients which makes it straightforward to demonstrate that formulary placement decisions were driven by rebate size rather than clinical value
IV insertion uses a small catheter similar to blood draws - most describe it as a quick pinch
Thermal adaptation in biological membranes: functional significance of changes in phospholipid molecular species composition
Another study, using dulaglutide, reported a medium-to-large effect size for reducing alcohol use in people with obesity, although no benefit was seen in heavy drinkers [35]